{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T06:48:21Z","timestamp":1794293301218,"version":"4.9.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:00:00Z","timestamp":1783123200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":88,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e0 degli Studi di Napoli Federico II","id":[{"id":"https:\/\/ror.org\/05290cv24","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Clin Immunol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Thymic epithelial tumors (TETs) are associated with Good Syndrome (GS), a secondary immunodeficiency characterized by hypogammaglobulinemia, B-cell lymphopenia, and recurrent infections. This study investigated the immunological profile of TET patients to identify immune alterations associated with GS, independently of autoimmune diseases (AD) and disease stage.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Seventy patients with TETs were stratified according to GS status (GS+\/GS\u2212), AD status (AD+\/AD\u2212), and disease stage (advanced disease, IVA\/B, or no evidence of disease, NED). Serum immunoglobulins, peripheral immune cell subsets, and circulating cytokines, chemokines, growth factors, and metabolic markers were evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>GS+ patients showed reduced IgM and IgG levels compared with GS- patients; however, after stratification, only IgM remained reduced in GS+AD\u2212 NED patients. Peripheral B-cell lymphopenia was consistently observed in GS+ patients across both disease stages, independently of AD status. Treg frequencies increased in GS\u2212 patients with advanced disease and in GS+AD+ NED patients. Monocytopenia and an inverted CD4+\/CD8+ ratio were mainly observed in GS+AD+ patients with advanced disease. Cytokine profiling identified increased levels of IL-1\u03b2, IL-10, IL-17, TNF\u03b1, IFN-\u03b3, IL-4, IL-5, IL-6, Eotaxin, G-CSF, and IP-10 in GS+ patients. Among these, IP-10 remained consistently elevated regardless of disease stage or AD status.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Peripheral B-cell lymphopenia and elevated IP-10 levels represent the most consistent immunological features associated with GS, independent of disease stage and AD status, whereas serum immunoglobulin levels appear less reliable in advanced disease. These findings support the diagnostic value of immunophenotyping, particularly B-cell quantification and IP-10 measurement, for identifying GS in patients with TETs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10875-026-02050-w","type":"journal-article","created":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T13:24:27Z","timestamp":1783171467000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Immunopathological Profile of Patients with Thymic Epithelial Tumour and Good Syndrome in Advanced Stage"],"prefix":"10.1007","volume":"46","author":[{"given":"Fabiana","family":"Napolitano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Pietroluongo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele Francesco","family":"Di Tolla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Ottaviano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittoria","family":"D\u2019Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"De Placido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Servetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Portella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Bianco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovannella","family":"Palmieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Formisano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Malfitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,4]]},"reference":[{"issue":"10","key":"2050_CR1","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/j.jtho.2023.06.015","volume":"18","author":"E Pietroluongo","year":"2023","unstructured":"Pietroluongo E, De Placido P, Tortora M, Martinelli C, Viggiano A, Saponaro MR, et al. Impaired seroconversion after severe acute respiratory syndrome coronavirus 2 mRNA vaccine in patients with thymic epithelial tumors. J Thorac Oncol. 2023;18(10):1399\u2013407.","journal-title":"J Thorac Oncol"},{"issue":"9 Suppl 2","key":"2050_CR2","doi-asserted-by":"publisher","first-page":"S65","DOI":"10.1097\/JTO.0000000000000290","volume":"9","author":"FC Detterbeck","year":"2014","unstructured":"Detterbeck FC, Stratton K, Giroux D, Asamura H, Crowley J, Falkson C, et al. The IASLC\/ITMIG thymic epithelial tumors staging project: proposal for an evidence-based stage classification system for the forthcoming (8th) edition of the TNM classification of malignant tumors. J Thorac Oncol. 2014;9(9 Suppl 2):S65\u201372.","journal-title":"J Thorac Oncol"},{"issue":"12","key":"2050_CR3","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/j.jtho.2023.09.002","volume":"18","author":"E Ruffini","year":"2023","unstructured":"Ruffini E, Huang J, Cilento V, Goren E, Detterbeck F, Ahmad U, et al. The International association for the study of lung cancer thymic epithelial tumors staging project: proposal for a stage classification for the forthcoming (Ninth) edition of the TNM classification of malignant tumors. J Thorac Oncol. 2023;18(12):1655\u201371.","journal-title":"J Thorac Oncol"},{"issue":"11","key":"2050_CR4","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1016\/j.jtho.2021.07.004","volume":"16","author":"M Chiappetta","year":"2021","unstructured":"Chiappetta M, Lococo F, Zanfrini E, Moroni R, Aprile V, Guerrera F, et al. The international thymic malignancy interest group classification of thymoma recurrence: survival analysis and perspectives. J Thorac Oncol. 2021;16(11):1936\u201345.","journal-title":"J Thorac Oncol"},{"key":"2050_CR5","doi-asserted-by":"publisher","first-page":"39","DOI":"10.21037\/med.2019.09.02","volume":"3","author":"N Girard","year":"2019","unstructured":"Girard N. Treatment options for stage IVA thymic malignancies. Mediastinum. 2019;3:39.","journal-title":"Mediastinum"},{"issue":"1","key":"2050_CR6","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.revmed.2017.03.003","volume":"39","author":"Y Jamilloux","year":"2018","unstructured":"Jamilloux Y, Frih H, Bernard C, Broussolle C, Petiot P, Girard N, S\u00e8ve P. [Thymoma and autoimmune diseases]. Rev Med Interne. 2018;39(1):17\u201326.","journal-title":"Rev Med Interne"},{"issue":"2","key":"2050_CR7","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1053\/j.semdp.2021.06.011","volume":"39","author":"J Prays","year":"2022","unstructured":"Prays J, Ortiz-Villal\u00f3n C. Molecular landscape of thymic epithelial tumors. Semin Diagn Pathol. 2022;39(2):131\u20136.","journal-title":"Semin Diagn Pathol"},{"key":"2050_CR8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.imlet.2020.12.010","volume":"231","author":"K Guevara-Hoyer","year":"2021","unstructured":"Guevara-Hoyer K, Fuentes-Antr\u00e1s J, Calatayud Gastardi J, S\u00e1nchez-Ram\u00f3n S. Immunodeficiency and thymoma in Good syndrome: Two sides of the same coin. Immunol Lett. 2021;231:11\u20137.","journal-title":"Immunol Lett"},{"key":"2050_CR9","doi-asserted-by":"publisher","first-page":"908453","DOI":"10.3389\/fimmu.2022.908453","volume":"13","author":"AM Malfitano","year":"2022","unstructured":"Malfitano AM, D\u2019Esposito V, De Placido P, Tortora M, Ottaviano M, Pietroluongo E, et al. Immunological signature of patients with thymic epithelial tumors and Good syndrome. Front Immunol. 2022;13:908453.","journal-title":"Front Immunol"},{"issue":"2","key":"2050_CR10","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1093\/cid\/civ269","volume":"61","author":"M Malphettes","year":"2015","unstructured":"Malphettes M, G\u00e9rard L, Galicier L, Boutboul D, Asli B, Szalat R, et al. Good syndrome: an adult-onset immunodeficiency remarkable for its high incidence of invasive infections and autoimmune complications. Clin Infect Dis. 2015;61(2):e13\u20139.","journal-title":"Clin Infect Dis"},{"key":"2050_CR11","doi-asserted-by":"publisher","first-page":"100230","DOI":"10.1016\/j.jtauto.2023.100230","volume":"8","author":"Y Xu","year":"2024","unstructured":"Xu Y, Wang L, Chen Z, Zhang Q, Shen Y, Ye Y, et al. Thymoma with immunodeficiency, combined diffuse panbronchiolitis, and latent autoimmune diabetes in adults- case report and systematic review. J Transl Autoimmun. 2024;8:100230.","journal-title":"J Transl Autoimmun"},{"issue":"1","key":"2050_CR12","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s00005-012-0207-9","volume":"61","author":"C Thongprayoon","year":"2013","unstructured":"Thongprayoon C, Tantrachoti P, Phatharacharukul P, Buranapraditkun S, Klaewsongkram J. Associated immunological disorders and cellular immune dysfunction in thymoma: a study of 87 cases from Thailand. Arch Immunol Ther Exp (Warsz). 2013;61(1):85\u201393.","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"issue":"7 Suppl 3","key":"2050_CR13","doi-asserted-by":"publisher","first-page":"S1710","DOI":"10.1097\/JTO.0b013e31821e8cff","volume":"6","author":"FC Detterbeck","year":"2011","unstructured":"Detterbeck FC, Nicholson AG, Kondo K, Van Schil P, Moran C. The Masaoka-Koga stage classification for thymic malignancies: clarification and definition of terms. J Thorac Oncol. 2011;6(7 Suppl 3):S1710\u20136.","journal-title":"J Thorac Oncol"},{"issue":"2","key":"2050_CR14","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.jtho.2021.10.010","volume":"17","author":"A Marx","year":"2022","unstructured":"Marx A, Chan JKC, Chalabreysse L, Dacic S, Detterbeck F, French CA, et al. The 2021 WHO classification of tumors of the thymus and mediastinum: what is new in thymic epithelial, germ cell, and mesenchymal tumors? J Thorac Oncol. 2022;17(2):200\u201313.","journal-title":"J Thorac Oncol"},{"key":"2050_CR15","first-page":"254319","volume":"2012","author":"A Rojas-Villarraga","year":"2012","unstructured":"Rojas-Villarraga A, Amaya-Amaya J, Rodriguez-Rodriguez A, Mantilla RD, Anaya JM. Introducing polyautoimmunity: secondary autoimmune diseases no longer exist. Autoimmune Dis. 2012;2012:254319.","journal-title":"Autoimmune Dis"},{"key":"2050_CR16","first-page":"137","volume":"19","author":"MF Di Tolla","year":"2025","unstructured":"Di Tolla MF, Romano S, Vassetti P, Perugini D, Filoso I, Cabaro S, et al. Platelet-derived growth factor as biomarker of clinical outcome for autologous platelet concentrate therapy in Grade I knee osteoarthritis. Biologics. 2025;19:137\u201347.","journal-title":"Biologics"},{"issue":"8","key":"2050_CR17","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1038\/s41366-021-00850-1","volume":"45","author":"V D\u2019Esposito","year":"2021","unstructured":"D\u2019Esposito V, Ambrosio MR, Liguoro D, Perruolo G, Lecce M, Cabaro S, et al. In severe obesity, subcutaneous adipose tissue cell-derived cytokines are early markers of impaired glucose tolerance and are modulated by quercetin. Int J Obes (Lond). 2021;45(8):1811\u201320.","journal-title":"Int J Obes (Lond)"},{"key":"2050_CR18","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ejim.2024.04.006","volume":"126","author":"C Wang","year":"2024","unstructured":"Wang C, Shi Y, Lim XR, Walter JE. The clinical spectrum of thymoma-associated immunodeficiency: Good syndrome and beyond. Eur J Intern Med. 2024;126:127\u20139.","journal-title":"Eur J Intern Med"},{"issue":"1","key":"2050_CR19","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1093\/oxfordjournals.qjmed.a068735","volume":"86","author":"RA Hermaszewski","year":"1993","unstructured":"Hermaszewski RA, Webster AD. Primary hypogammaglobulinaemia: a survey of clinical manifestations and complications. Q J Med. 1993;86(1):31\u201342.","journal-title":"Q J Med"},{"issue":"3","key":"2050_CR20","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.clim.2010.01.006","volume":"135","author":"T Kelesidis","year":"2010","unstructured":"Kelesidis T, Yang O. Good\u2019s syndrome remains a mystery after 55 years: A systematic review of the scientific evidence. Clin Immunol. 2010;135(3):347\u201363.","journal-title":"Clin Immunol"},{"key":"2050_CR21","doi-asserted-by":"publisher","first-page":"114456","DOI":"10.1016\/j.intimp.2025.114456","volume":"153","author":"M Rokni","year":"2025","unstructured":"Rokni M, Khomeijani-Farahani M, Soltani T, Jamshidi A, Mahmoudi M, Farhadi E. Understanding the pleiotropic effects of CXCL10\/IP-10 in the immunopathogenesis of inflammatory rheumatic diseases: Implications for better understanding disease mechanisms. Int Immunopharmacol. 2025;153:114456.","journal-title":"Int Immunopharmacol"},{"issue":"10","key":"2050_CR22","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1084\/jem.20112142","volume":"209","author":"W Xu","year":"2012","unstructured":"Xu W, Joo H, Clayton S, Dullaers M, Herve MC, Blankenship D, et al. Macrophages induce differentiation of plasma cells through CXCL10\/IP-10. J Exp Med. 2012;209(10):1813\u201323. s1-2.","journal-title":"J Exp Med"},{"key":"2050_CR23","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.coi.2018.09.002","volume":"55","author":"BE Jones","year":"2018","unstructured":"Jones BE, Maerz MD, Buckner JH. IL-6: a cytokine at the crossroads of autoimmunity. Curr Opin Immunol. 2018;55:9\u201314.","journal-title":"Curr Opin Immunol"},{"issue":"4","key":"2050_CR24","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.immuni.2008.02.017","volume":"28","author":"YP Rubtsov","year":"2008","unstructured":"Rubtsov YP, Rasmussen JP, Chi EY, Fontenot J, Castelli L, Ye X, et al. Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. Immunity. 2008;28(4):546\u201358.","journal-title":"Immunity"},{"issue":"8","key":"2050_CR25","doi-asserted-by":"publisher","first-page":"3665","DOI":"10.4049\/jimmunol.1402898","volume":"195","author":"P Hsu","year":"2015","unstructured":"Hsu P, Santner-Nanan B, Hu M, Skarratt K, Lee CH, Stormon M, et al. IL-10 Potentiates differentiation of human induced regulatory T Cells via STAT3 and Foxo1. J Immunol. 2015;195(8):3665\u201374.","journal-title":"J Immunol"},{"key":"2050_CR26","doi-asserted-by":"publisher","first-page":"101325","DOI":"10.1016\/j.smim.2019.101325","volume":"44","author":"M Oft","year":"2019","unstructured":"Oft M. Immune regulation and cytotoxic T cell activation of IL-10 agonists - Preclinical and clinical experience. Semin Immunol. 2019;44:101325.","journal-title":"Semin Immunol"}],"container-title":["Journal of Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10875-026-02050-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-026-02050-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-026-02050-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:56:23Z","timestamp":1790726183000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10875-026-02050-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,4]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2050"],"URL":"https:\/\/doi.org\/10.1007\/s10875-026-02050-w","relation":{},"ISSN":["1573-2592"],"issn-type":[{"value":"1573-2592","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,4]]},"assertion":[{"value":"8 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Ethics Committee of the University of Naples Federico II (approval n.76.21). All patients provided written informed consent before enrollment per institutional guidelines and the Declaration of Helsinki.","order":1,"name":"Ethics","label":"Ethics Approval and Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All enrolled patients signed an informed consent at the study entrance.","order":2,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"91"}}